RCKT Rocket Corp: Enterprise Value to EBITDA Ratio
Rocket Pharmaceuticals (RCKT) specializes in developing innovative drugs for the treatment of severe genetic pathologies. This chart reflects the current market value on GURU.Markets at 0.00, confirming its status as a global innovator that enjoys deep trust from the medical community. The executive team demonstrates proficiency in navigating FDA approvals, confidently transitioning developments into the commercial stage. However, a lack of diversification and dependence on a narrow pipeline of drugs create high risks for investors.
Comprehensive metric breakdowns and analytics for rocketpharma.com (RCKT)
- current price and projected stock value:
- company stock capitalization data:
- business book valuation details:
- debt obligations and liquidity statistics:
Total Debt to Capital Rocket Pharmaceuticals|RCKT - Long-Term Debt to Capital Coefficient|Short-Term Debt to Capital Rocket Pharmaceuticals, Inc.|RCKT - Company Aggregate Debts|Debt to Book Capitalization Ratio Rocket Corp|RCKT - Company Long-Term Loans and Borrowings|Company Short-Term Debt Rocket Pharmaceuticals|Quick Ratio rocketpharma.com
- net income and valuation multiples indicators:
RCKT - Net Profit|Projected Future Earnings Rocket Pharmaceuticals|RCKT - Price to Earnings Ratio|Forward P/E Multiple Rocket Pharmaceuticals|RCKT - Price to Earnings Adjusted for Growth Rate|Enterprise Value to EBITDA Ratio Rocket Corp|RCKT - Operating profit EBITDA|Net earnings per share for the last 12 months Rocket Pharmaceuticals|RCKT - Earnings per share for the last four quarters|Quarterly EPS earnings growth rocketpharma.com|RCKT - Expected net earnings per share growth this year|Earnings growth forecast for next year Rocket Pharmaceuticals
Fundamental company analysis:RCKT (Rocket Pharmaceuticals Inc)
This ratio determines the business value relative to its operating profit, accounting for debt load and tax obligations. For Rocket Pharmaceuticals (RCKT), which operates in the non-cyclical gene therapy sector, the EV/EBITDA multiple trend reflects market expectations regarding drug approvals. The current value of 0.00 serves as a risk premium indicator. The stability of this metric confirms the fundamental resilience of Rocket Pharmaceuticals regardless of macroeconomic fluctuations.
Key competitors
EV/EBITDA Multiple TEM (tempus.com)|Qiagen Corp (QGEN) - Company Value to EBITDA|IONS: Enterprise Value to EBITDA Ratio|repligen.com - Enterprise Value to Operating Income Before Depreciation Ratio|RNA (Avidity Biosciences, Inc.) - Enterprise Value to EBITDA Ratio|CRISPR Therapeutics Inc - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Sema4|Ultragenyx Corp - Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple BEAM|SRPT (sarepta.com) - Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple TWST (Twist Bioscience, Inc.)|EV/EBITDA Multiple 10x Genomics Inc TXG|NTLA - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Business Value to Operating Income Before Depreciation STOK (Stoke Corp)|BioLife Solutions, Inc. (BLFS) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to EBITDA Ratio wavelifesciences.com|MAZE (Maze Therapeutics) - EV/EBITDA Multiple|EV/EBITDA Multiple Sionna Therapeutics, Inc.|EV/EBITDA Multiple PRME|Enterprise Value to EBITDA Ratio Taysha Corp TSHA|EV/EBITDA Multiple QURE (uniQure N.V.)|meiragtx.com (MGTX) - Company Value to EBITDA|RGNX: Enterprise Value to EBITDA Ratio|SLDB - EV/EBITDA Multiple|OCGN (Ocugen Corp) - Enterprise Value to EBITDA Ratio|PACB: Enterprise Value to Operating Income Before Depreciation Ratio|BNTC (Benitec Biopharma Inc.) - EV/EBITDA Multiple|designtx.com (DSGN) - Total Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple FDMT|Enterprise Value to EBITDA Ratio lexeotx.com LXEO|EV/EBITDA Multiple KRRO (Korro Bio)|EV/EBITDA Multiple Editas Corp EDIT|SLN - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|PRQR: Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|codexis.com (CDXS) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|SGMO - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Nautilus Biotechnology, Inc.|MGX: Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple DTIL|Enterprise Value to EBITDA Ratio generationbio.com GBIO|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Boundless Bio BOLD|EV/EBITDA Multiple Exicure Inc. XCUR|IMNN: Enterprise Value to EBITDA Ratio|Phio Pharmaceuticals - Enterprise Value to Operating Income Before Depreciation Ratio|MBIO: EV/EBITDA Multiple|Enterprise Value to Operating Income Before Depreciation RNAZ|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Bionano Genomics Inc.|Enterprise Value to Operating Income Before Depreciation APDN (Applied DNA Sciences Inc)|EV/EBITDA Multiple BLUE|EV/EBITDA Multiple immunoprecise.com (IPA)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Omega Therapeutics OMGA|Business Value to Operating Income Before Depreciation OMIC|RGLS - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA Syros Pharmaceuticals Inc.|TBIO: EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio TRACON Pharmaceuticals, Inc|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Unity Biotechnology
